When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

斑秃

最后审阅: 4 Oct 2024
最后更新: 23 Sep 2022
23 Sep 2022

FDA 和 EMA 批准巴瑞替尼用于治疗成人重度斑秃

巴瑞替尼是一种 Janus 激酶(Janus kinase, JAK)抑制剂,是首个被美国食品药品监督管理局和欧洲药品管理局批准用于治疗成人重度斑秃的全身性药物。该批准是基于两项随机安慰剂对照 3 期试验,试验证明,与安慰剂相比,口服巴瑞替尼可提高重度斑秃患者 36 周时的毛发再生。不良反应包括痤疮、肌酸激酶水平升高以及低、高密度脂蛋白胆固醇水平升高。[26]

查看治疗:新兴治疗

更新原始来源

小结

定义

病史和体格检查

关键诊断因素

  • 脱发
  • 非瘢痕性秃发
  • 惊叹号样发
  • 在秃发区皮肤表现正常
  • 顶针样甲
完整详情

其他诊断因素

  • 自身免疫
完整详情

危险因素

  • 自身免疫性疾病
  • 自身免疫病的家族史
完整详情

诊断性检查

首要检查

  • 临床诊断
  • 拔发试验阳性
完整详情

需考虑的检查

  • 皮肤活组织检查
  • 毛发镜检查
完整详情

治疗流程

急症处理

局限性脱发(需要治疗)

局限性脱发(不需要治疗)

持续性治疗

广泛性脱发(需要治疗)

广泛性脱发(不需要治疗)

撰稿人

作者

Fong Seng Lim, MBBS, MMed (FM), FAMS

Senior Consultant

Department of Family Medicine

National University Health System

Singapore

利益声明

FSL declares that he has no competing interests.

Miny Samuel, PhD

Assistant Director

Research Support Unit

Yong Loo Lin School of Medicine

National University of Singapore

Singapore

利益声明

MS declares that she has no competing interests.

鸣谢

Dr Fong Seng Lim and Dr Miny Samuel would like to gratefully acknowledge Dr Richard A. Strick, Dr Jack Green, and Dr Paradi Mirmirani, previous contributors to this topic. RAS is an honorary member of the National Alopecia Areata Foundation (NAAF) clinical scientific advisory board. JG is an author of a reference cited in this topic. PM declares that he has no competing interests.

同行评议者

Maria Hordinsky, MD

Professor and Chair

Department of Dermatology

University of Minnesota

Minneapolis

MN

利益声明

MH declares that she has no competing interests.

Ralph M. Trueb, MD

Associate Professor

Department of Dermatology

University Hospital of Zurich

Zurich

Switzerland

利益声明

RMT is an author of a number of references cited in this topic.

内容使用需遵循免责声明